Gene Therapy Market Size is valued at USD 2.4 Bn in 2024 and is predicted to reach USD 13.6 Bn by the year 2034 at a 19.05% CAGR during the forecast period for 2025-2034
Gene therapy is a therapeutic approach that targets the fundamental genetic problem in order to treat or prevent diseases. Gene therapy offers an alternative to medications or surgery, enabling doctors to address a condition by modifying an individual's genetic makeup. Gene therapy is now able to treat a limited number of conditions, such as Leber congenital amaurosis, an eye condition, spinal muscular atrophy, a muscle condition. Several alternative gene therapies are being investigated to ensure their efficacy and safety. Medical professionals aim to apply the promising genome editing technique soon to cure human illnesses.
The development of the gene therapy market is due to the increasing occurrence of genetic disorders and rare diseases. These conditions, previously considered incurable, are now being targeted with innovative gene therapies that offer potential cures or significant symptom alleviation. Additionally, biotechnology and molecular biology advancements have improved our understanding of gene function and regulation, enabling the advancement of more precise and effective therapies. The gene therapy market has witnessed substantial growth and advancements in recent years, signifying a transformative era in medical treatment.
However, the high cost of gene therapy products presents a challenge in the gene therapy market. These cutting-edge treatments offer promising solutions for genetic disorders and diseases, but their prohibitive prices can limit patient access and strain healthcare systems. Striking a balance between affordability and rewarding innovation is critical. Regulatory agencies, healthcare providers, and pharmaceutical companies must collaborate to develop pricing models that ensure equitable access to gene therapies while incentivizing further research and development in this transformative field.
The Gene therapy market segmentation is based on type, Vector, therapeutic area, delivery method, and route of administration. Based on type, the market is segmented into gene silencing, cell replacement, gene augmentation, and other therapies. As per the therapeutic areas, the market is segmented into neurology, oncology, hepatology, and other therapeutic areas. According to vectors, the market is segmented into Viral vectors (Retroviral Vectors (Gamma Retroviral Vectors, Lentiviral Vectors), Adeno-Associated Viral Vectors, Other Viral Vectors), Non-Viral Vectors (Oligonucleotides, and Other Non-Viral Vectors). As per the the delivery method, the market is segmented as in Vivo and Ex Vivo. The route of administration segment includes intravenous other routes of administration.
Gene slicing is a vital technique within the gene therapy market, allowing for the precise modification of genetic material. This technology's driving force lies in its potential to treat genetic disorders, including inherited diseases, by replacing or repairing faulty genes. As gene therapy advances, the ability to accurately splice genes becomes crucial for developing targeted and effective treatments. This innovative approach holds promise for improved patient outcomes and has the potential to transform the healthcare landscape by providing personalized solutions for genetic conditions.
The neurology gene therapy market is driven by the potential to treat previously untreatable neurological disorders through genetic interventions. Advancements in gene therapy techniques offer hope for conditions like Parkinson's disease and ALS. This evolving field leverages innovative technologies to target the genetic root causes of neurological ailments, with promising results in preclinical and clinical trials. As the understanding of neurogenetics deepens and the safety and efficacy of gene therapies improve, the market is poised to grow, offering new therapeutic options for patients with challenging neurological conditions.
The North American gene therapy market is driven by several factors, with one prominent driver being robust research and development initiatives. The region's advanced healthcare infrastructure, substantial investment in biotechnology, and supportive regulatory frameworks encourage innovation and the development of cutting-edge gene therapies. This fosters collaboration between academic institutions, pharmaceutical companies, and startups, creating a dynamic landscape for gene therapy advancements.
Additionally, the increasing prevalence of genetic disorders and the demand for personalized medicine contribute to the market's growth, making North America a hub for gene therapy research and adoption. In addition, Asia Pacific is estimated to grow rapidly in the global gene therapy market due to its large population with unmet medical requirements and increasing demand for novel technologies to treat rare but increasingly prevalent diseases.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 2.4 Bn |
|
Revenue Forecast In 2034 |
USD 13.6 Bn |
|
Growth Rate CAGR |
CAGR of 19.05% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, By Therapeutic area, By Delivery method, By Route Of Administration |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Novartis Ag, Biogen Inc., Gilead Sciences, Inc., Bristol-Myers Squibb, Alnylam Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Amgen, Inc., Orchard Therapeutics Plc, F. Hoffmann-La Roche Ag, Jazz Pharmaceuticals Plc, Uniqure N.V., Johnson & Johnson, Bluebird Bio, Inc., Biomarin Pharmaceutical Inc., Krystal Biotech, Inc., Shanghai Sunway Biotech Co. Ltd., Sibiono Genetech Co. Ltd., Ferring B.V., Vertex Pharmaceuticals Incorporated, Pfizer, Inc., Sangamo Therapeutics, Inc., egenxbio, Ultragenyx Pharmaceutical Inc., Meiragtx Holdings Plc, Anges, Inc. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Gene Therapy Market Snapshot
Chapter 4. Global Gene Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Type Estimates & Trend Analysis
5.1. By Type, & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Type:
5.2.1. Gene silencing
5.2.2. Cell replacement
5.2.3. Gene augmentation
5.2.4. Other therapies
Chapter 6. Market Segmentation 2: By Vector Estimates & Trend Analysis
6.1. By Vector & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Vector:
6.2.1. Viral vectors
6.2.2. Non-Viral vectors
Chapter 7. Market Segmentation 3: By Delivery method Estimates & Trend Analysis
7.1. By Delivery method & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Delivery method:
7.2.1. In Vivo
7.2.2. Ex Vivo
Chapter 8. Market Segmentation 4: By Route of administration Estimates & Trend Analysis
8.1. By Route of administration & Market Share, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Route of administration:
8.2.1. Intravenous
8.2.2. Other routes of administration
Chapter 9. Market Segmentation 5: By Therapeutic Area Estimates & Trend Analysis
9.1. By Therapeutic Area & Market Share, 2024 & 2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Therapeutic Area:
9.2.1. Neurology
9.2.2. Oncology
9.2.3. Hepatology
9.2.4. Other therapeutic areas
Chapter 10. Gene Therapy Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. North America
10.1.1. North America Gene Therapy Market revenue (US$ Million) estimates and forecasts By Type, 2021-2034
10.1.2. North America Gene Therapy Market revenue (US$ Million) estimates and forecasts By Vector, 2021-2034
10.1.3. North America Gene Therapy Market revenue (US$ Million) estimates and forecasts By Delivery method, 2021-2034
10.1.4. North America Gene Therapy Market revenue (US$ Million) estimates and forecasts By Route of administration, 2021-2034
10.1.5. North America Gene Therapy Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2021-2034
10.1.6. North America Gene Therapy Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
10.2. Europe
10.2.1. Europe Gene Therapy Market revenue (US$ Million) By Type, 2021-2034
10.2.2. Europe Gene Therapy Market revenue (US$ Million) By Vector, 2021-2034
10.2.3. Europe Gene Therapy Market revenue (US$ Million) By Delivery method, 2021-2034
10.2.4. Europe Gene Therapy Market revenue (US$ Million) By Route of administration, 2021-2034
10.2.5. Europe Gene Therapy Market revenue (US$ Million) By Therapeutic Area, 2021-2034
10.2.6. Europe Gene Therapy Market revenue (US$ Million) by country, 2021-2034
10.3. Asia Pacific
10.3.1. Asia Pacific Gene Therapy Market revenue (US$ Million) By Type, 2021-2034
10.3.2. Asia Pacific Gene Therapy Market revenue (US$ Million) By Vector, 2021-2034
10.3.3. Asia Pacific Gene Therapy Market revenue (US$ Million) By Delivery method, 2021-2034
10.3.4. Asia Pacific Gene Therapy Market revenue (US$ Million) By Route of administration, 2021-2034
10.3.5. Asia Pacific Gene Therapy Market revenue (US$ Million) By Therapeutic Area, 2021-2034
10.3.6. Asia Pacific Gene Therapy Market revenue (US$ Million) by country, 2021-2034
10.4. Latin America
10.4.1. Latin America Gene Therapy Market revenue (US$ Million) By Type, (US$ Million) 2021-2034
10.4.2. Latin America Gene Therapy Market revenue (US$ Million) By Vector, (US$ Million) 2021-2034
10.4.3. Latin America Gene Therapy Market revenue (US$ Million) By Delivery method, (US$ Million) 2021-2034
10.4.4. Latin America Gene Therapy Market revenue (US$ Million) By Route of administration, (US$ Million) 2021-2034
10.4.5. Latin America Gene Therapy Market revenue (US$ Million) By Therapeutic Area, (US$ Million) 2021-2034
10.4.6. Latin America Gene Therapy Market revenue (US$ Million) by country, 2021-2034
10.5. Middle East & Africa
10.5.1. Middle East & Africa Gene Therapy Market revenue (US$ Million) By Type, (US$ Million) 2021-2034
10.5.2. Middle East & Africa Gene Therapy Market revenue (US$ Million) By Vector, (US$ Million) 2021-2034
10.5.3. Middle East & Africa Gene Therapy Market revenue (US$ Million) By Delivery method, (US$ Million) 2021-2034
10.5.4. Middle East & Africa Gene Therapy Market revenue (US$ Million) By Route of administration, (US$ Million) 2021-2034
10.5.5. Middle East & Africa Gene Therapy Market revenue (US$ Million) By Therapeutic Area, (US$ Million) 2021-2034
10.5.6. Middle East & Africa Gene Therapy Market revenue (US$ Million) by country, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Novartis AG (Switzerland),
11.2.2. Biogen Inc. (US),
11.2.3. Gilead Sciences, Inc. (US),
11.2.4. Bristol-Myers Squibb (US),
11.2.5. Alnylam Pharmaceuticals, Inc. (US),
11.2.6. Sarepta Therapeutics, Inc. (US)
Gene Therapy Market By Type
Gene Therapy Market By Vector
Gene Therapy Market By Therapeutic area
Gene Therapy Market By Delivery method
Gene Therapy Market By Route of administration
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
